NerdWallet's future growth may disappoint despite past performance and robust revenue growth, due to their high P/S ratio and significant risks. The current share prices could be unsustainable long-term due to potential lower revenue growth.
Despite the recent gains, NerdWallet's high price-to-sales ratio may not be justified given the slower-than-industry growth forecast. There's a risk of future disappointment for investors if the P/S falls to levels more in line with the growth outlook.
NerdWallet's CEO sees the new card as a triple win - a useful tool for consumers to establish credit affordably, larger customer base for banks and a wider, engaged audience for NerdWallet, though the company won't directly monetize the card.
Gainers: •$バリーズ・コーポレーション(BALY.US)$+6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22) •$ファーガソン(FERG.US)$+3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program) •$ボシュ・ヘルス・カンパニーズ(BHC.US)$+3.3% (chairman resigns) •$サノフィ(SNY.US)$+3.2% (Sanofi-GSK first to report a successful efficacy study against ...
ナードウォレットに関するコメント
⚠️ Stocks are Crashing…
Top Stocks to Buy Now!!
$ナードウォレット(NRDS.US)$$アメリカン・タワー(AMT.US)$$ナショナル・ストレージ・アフィリエイト・トラスト(NSA.US)$$エクストラ・スペース・ストレージ(EXR.US)$$デボン・エナジー(DVN.US)$$ネクステラ・エナジー(NEE.US)$$ネクステラ・エナジー・パートナーズ(NEP.US)$$ペン・エンターテインメント(PENN.US)$
11/3 Watchlist
$チューイー(CHWY.US)$$コインベース(COIN.US)$$データドッグ(DDOG.US)$$ドラフト・キングス(DKNG.US)$$フォルツァX1(FRZA.US)$$ナードウォレット(NRDS.US)$$ペイパル(PYPL.US)$$クアルコム(QCOM.US)$$ロク(ROKU.US)$$トゥイリオ(TWLO.US)$
コラムToday's pre-market stock movers: FDX, REV, BCS, KMX and more
• $バリーズ・コーポレーション(BALY.US)$ +6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22)
• $ファーガソン(FERG.US)$ +3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program)
• $ボシュ・ヘルス・カンパニーズ(BHC.US)$ +3.3% (chairman resigns)
• $サノフィ(SNY.US)$ +3.2% (Sanofi-GSK first to report a successful efficacy study against ...
まだコメントはありません